Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Nexstim Plc
With the global pandemic leading to a big rise in mental health issues, medtech could have a role to play. In Vivo explores transcranial magnetic stimulation systems that are being used to treat severe anxiety and depression, among other indications. As well as the skyrocketing use of telehealth, apps and light therapy for mental health indications.
Neuromodulation firm Nexstim has received regulatory clearance for its SmartFocus TMS system for treating major depressive disorder (MDD) in Australia.
Neuromodulation firm Nexstim will launch its SmartFocus TMS system for treating major depressive disorder (MDD) in Canada after signing an exclusive agreement with distributor Canada Health Solutions CHS.
The Helsinki-based company had expected stroke rehabilitation to be the first FDA-cleared indication for its Navigated Brain Therapy system, but while more data is collected for that program, it is pursuing a 510(k) clearance for NBS to treat major depressive disorder and plans to build a US salesforce to market NBS for therapeutic indications.
- Medical Devices
- Consumables, Central Supplies
- Implantable Devices
- Infection Control-Sterilization
- Infusion Therapy Equipment and Supplies
- Monitoring Equipment & Devices
- Radiofrequency Devices
- Rehabilitation Equipment and Devices
Surgical Equipment & Devices
- Minimally or Less Invasive
Diagnostic Imaging Equipment & Supplies
- Digital Imaging
- MRI, NMR
- Other Names / Subsidiaries
- Nexstim Germany GmbH
- Nexstim Inc
- Nexstim Ltd.